Skip to main content
LBRX
NASDAQ Life Sciences

LB Pharmaceuticals Launches Pivotal Phase 3 Schizophrenia Trial, Secures Cash Runway into 2029

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$31.13
Mkt Cap
$892.647M
52W Low
$13.36
52W High
$33.47
52W Position info
133% above low
Off High info
7.0% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

LBRX has more than doubled off its 52-week low of $13.36 on light trading volume (0.4× avg).

Summary

LB Pharmaceuticals announced the initiation of its pivotal Phase 3 NOVA-2 trial for LB-102 in schizophrenia and a Phase 2 ILLUMINATE-1 trial for bipolar depression, marking significant clinical progress for its lead candidate. The company reported a robust cash position of $365.6 million as of March 31, 2026, which is expected to fund operations into the second quarter of 2029, largely supported by a $100 million private placement in February. This extended cash runway provides critical financial stability to advance multiple late-stage clinical programs. Additionally, positive results from the Phase 2 NOVA-1 trial in schizophrenia, demonstrating a direct cognitive benefit from LB-102, were published in JAMA Psychiatry, further validating the drug's potential. Traders will be watching for topline data from the NOVA-2 trial in the second half of 2027 and ILLUMINATE-1 in the first quarter of 2028 as key future catalysts.

At the time of this announcement, LBRX was trading at $31.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $892.6M. The 52-week trading range was $13.36 to $33.47. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LBRX - Latest Insights

LBRX
Nov 05, 2026, 8:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Nov 05, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Oct 01, 2026, 4:05 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $37.28
Real-time Price: $38.85 info
Change: +$1.57 (+4%) info
Market Cap: $1.257B info
LBRX
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.76
Real-time Price: $38.85 info
Change: -$7.91 (-17%) info
Market Cap: $1.257B info